References
- Aman M. G., Wolford P. L. Consumer satisfaction with involvement in drug research: A social validity study. Journal of the American Academy of Child and Adolescent Psychiatry 1995; 34: 940–945
- Harris J. 2006. Intellectual disability: Understanding its development, causes, classification, evaluation, and treatment. 382-392. Oxford University Press. 2006 (see also http://videocast.nih.gov/PastEvents.asp?c = 1&s = 191; click on “Past Events” and choose cluster corresponding to November/December 2001)
- Iacono T. Ethical challenges and complexities of including people with intellectual disability as participants in research. Journal of Intellectual & Developmental Disability 2006; 31: 173–179
- McAdam D. B., Zarcone J. R., Hellings J., Napolitano D. A., Schroeder S. R. Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures. American Journal on Mental Retardation 2002; 107: 261–269
- Schouten R., Duckworth K. S. Medico‐legal and ethical issues in the pharmacologic treatment of children. Werry J. S, Aman M. G. Plenum Press, New York 1999, Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 165–181)
- Tierney E., Aman M. G., Stout D. J., Pappas K., Arnold L. E., Vitiello B., et al. Parent satisfaction in a multi‐site trial of risperidone in children with autism: A social validity study. Psychopharmacology. in press